Celera Genomics Submits Human Genome Manuscript for Publication.

Business Editors/Science & Medical Writers

ROCKVILLE, Md.--(BW HealthWire)--Dec. 6, 2000

Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today that it has submitted the manuscript on the human genome to a premier scientific journal, Science. The paper is now undergoing scientific peer review. It is expected that this paper will be published in early 2001. Celera continues discussions with the International Public Human Sequencing Consortium to coordinate simultaneous publication.

Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. To achieve this goal, it has developed an on-line information business built upon the generation, aggregation, integration, and analysis of biological data. Its databases are believed to be the most extensive in the industry today. The Applied Biosystems Group (NYSE: ABI) develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules and proteins in order to make scientific discoveries, develop new pharmaceuticals and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about the Company, including reports and other information filed by the Company with the Securities and Exchange Commission, is available on the world wide web at www.applera.com. Alternatively, information is available by phoning 800/762-6923.

Applera, Celera, and Celera Genomics are trademarks and Applied Biosystems, is a registered trademark of Applera Corporation or its subsidiaries in the US and certain other countries.